Accéder au contenu
Merck

CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation.

Cell death and differentiation (2020-11-10)
Yina Liao, Yijun Hua, Yizhuo Li, Changlin Zhang, Wendan Yu, Ping Guo, Kun Zou, Wenyang Li, Yao Sun, Ruozhu Wang, Yan Zuo, Silei Sui, Chunfang Tian, Jiaojiao Hao, Manyu Chen, Sheng Hu, Miao Chen, Qian Long, Xiaonan Wang, Lijuan Zou, Fangyun Xie, Wei Guo, Wuguo Deng
RÉSUMÉ

CRSP8 plays an important role in recruiting mediators to genes through direct interaction with various DNA-bound transactivators. In this study, we uncovered the unique function of CRSP8 in suppressing thyroid cancer differentiation and promoting thyroid cancer progression via targeting IKKα signaling. CRSP8 was highly expressed in human thyroid cancer cells and tissues, especially in anaplastic thyroid cancer (ATC). Knockdown of CRSP8 suppressed cell growth, migration, invasion, stemness, and induced apoptosis and differentiation in ATC cells, while its overexpression displayed opposite effects in differentiated thyroid cancer (DTC) cells. Mechanistically, CRSP8 downregulated IKKα expression by binding to the IKKα promoter region (-257 to -143) to negatively regulate its transcription. Knockdown or overexpression of IKKα significantly reversed the expression changes of the differentiation and EMT-related markers and cell growth changes mediated by CRSP8 knockdown or overexpression in ATC or DTC cells. The in vivo study also validated that CRSP8 knockdown inhibited the growth of thyroid cancer by upregulating IKKα signaling in a mouse model of human ATC. Furthermore, we found that CRSP8 regulated the sensitivity of thyroid cancer cells to chemotherapeutics, including cisplatin and epirubicin. Collectively, our results demonstrated that CRSP8 functioned as a modulator of IKKα signaling and a suppressor of thyroid cancer differentiation, suggesting a potential therapeutic strategy for ATC by targeting CRSP8/IKKα pathway.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
cis-Diammineplatinum(II) dichloride, crystalline
Sigma-Aldrich
Epirubicin hydrochloride, ≥90% (HPLC)